
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell is a promising medical technology company that has developed the Ceribell System, a novel point-of-care electroencephalography platform that addresses unmet needs in the acute care setting. The company is gaining significant commercial traction and expects to see a +19% increase in headband use for delirium. With a strong financial profile and a pipeline full of new algorithm clearances and a next-generation hardware platform, the company's revenue and gross margins are expected to continue to grow. Additionally, the company is actively investing in its salesforce and pipeline to drive near-term and long-term growth, making it a buy for investors.
Bears say
CeriBell is poised for moderate growth in net new accounts and utilization for its Ceribell EEG System due to consistent demand in ICU and ER hospital settings, with potential for increase in pediatric use. The company's improvement in 2026 gross margin and operating spend reflects a strong financial outlook. However, geopolitical tensions, competition, and regulatory decisions pose potential risks for the company's growth and stock performance.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares